flutamide has been researched along with Adenocarcinoma in 195 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This single institution, randomized, double-blind, placebo controlled study compared flutamide in the dose of 250 mg three times daily (n = 23) versus placebo (n = 23) in patients with histologically proven, previously untreated unresectable pancreatic adenocarcinoma." | 9.12 | Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial. ( Agarwal, A; Chaudhary, A; Negi, SS, 2006) |
| " We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate." | 9.08 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997) |
| " This paper demonstrated that flutamide combined with leuprorelin acetate produced a significant reduction in the growth rate of Dunning R3327-H prostatic adenocarcinoma." | 7.70 | [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats]. ( Abe, F; Kuroiwa, S; Okada, M; Tomura, A, 1998) |
| "To assess the effectiveness of palladium 103 (Pd-103) brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate." | 7.70 | Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. ( Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z, 1998) |
| "To assess the effectiveness of palladium-103 brachytherapy in stage T1 and T2 adenocarcinoma of the prostate." | 7.70 | Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. ( Behar, RJ; Cantor, A; Chovnick, SD; Donohue, M; Huff, W; Otheguy, J; Perez, R; Rabinowitz, R; Sharkey, J; Solc, Z; Steele, J; Webster, C, 2000) |
| "Three of 34 patients treated with a TAS regimen incorporating flutamide developed significant hepatic abnormalities: elevated transaminases [2] and fatal hepatic necrosis [1]." | 7.69 | Flutamide-induced liver toxicity including fatal hepatic necrosis. ( Chen, A; Crownover, RL; Fu, KK; Holland, J; Krieg, R; Roach, M; Young, BK, 1996) |
| "We report a primary squamous cell carcinoma of the prostate that developed in a 57-year-old man, 3 years after treatment with leuprolide and flutamide for Stage D1 adenocarcinoma of the prostate." | 7.69 | Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide. ( Braslis, KG; Civantos, F; Davi, RC; Nelson, E; Soloway, MS, 1995) |
| "The histopathology of 23 radical prostatectomies from patients with prostatic adenocarcinoma pretreated for 3-6 months with combination therapy including a luteinizing hormone-releasing hormone agonist and the antiandrogen drug flutamide was reviewed and compared with the pretreatment biopsies or transurethral resection material." | 7.68 | Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. ( Boivin, JC; Dupont, A; Labrie, F; Monfette, G; Pinault, S; Srigley, JR; Têtu, B, 1991) |
| "A seventy-three year-old patient with prostate cancer underwent radical prostatectomy, followed by total androgen brocking therapy using flutamide and LH-RH agonist." | 5.30 | [Fatal hepatic failure following hepatitis caused by flutamide: a case report]. ( Kinebuchi, Y; Murata, Y; Okaneya, T, 1999) |
| "Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3." | 5.24 | Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. ( Bedi, M; Brereton, HD; Dignam, JJ; Grignon, DJ; Hanks, GE; Horwitz, EM; Kim, H; Kwok, Y; Lawton, CAF; Lepor, H; Lin, X; Parliament, MB; Pisansky, TM; Rabinovitch, R; Roach, M; Rosenthal, SA; Sandler, HM; Venkatesan, VM; Zeitzer, KL, 2017) |
| "This single institution, randomized, double-blind, placebo controlled study compared flutamide in the dose of 250 mg three times daily (n = 23) versus placebo (n = 23) in patients with histologically proven, previously untreated unresectable pancreatic adenocarcinoma." | 5.12 | Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial. ( Agarwal, A; Chaudhary, A; Negi, SS, 2006) |
| "We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo." | 5.08 | Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. ( Blumenstein, BA; Bueschen, AJ; Crawford, ED; Culkin, DJ; Eisenberger, MA; Loehrer, PJ; Lowe, BA; McLeod, DG; Miller, G; Sears, K; Thompson, IM; Wilding, G, 1998) |
| " We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate." | 5.08 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997) |
| "In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double-blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo." | 5.07 | The use of flutamide in hormone-refractory metastatic prostate cancer. ( Benson, RC; Blumenstein, BA; Crawford, ED; Eisenberger, MA; McLeod, DG; Spaulding, JT; Spicer, D, 1993) |
| " We investigated the effects of the proteasome inhibitors MG115 and PSI alone or in combination with different concentrations of the antiandrogen hydroxyflutamide on the cellular proliferation, apoptosis and viability of 10 prostatic adenocarcinoma cell cultures." | 3.72 | Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures. ( Stöckle, M; Tahmatzopoulos, A; Unteregger, G; Wullich, B; Zwergel, T; Zwergel, U, 2004) |
| "One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid)." | 3.72 | Anemia in patients on combined androgen block therapy for prostate cancer. ( Cheng, SG; Hua, LX; Li, J; Qian, LX; Sui, YG; Wang, XR; Wu, HF; Zhang, W, 2004) |
| " Here we report AR gene mutations identified in human prostate cancer and the autochthonous transgenic adenocarcinoma of the mouse prostate model that colocate to residues (668)QPIF(671) at the boundary of the hinge and ligand-binding domain, resulting in receptors that exhibit 2- to 4-fold increased activity compared with wild-type AR in response to dihydrotestosterone, estradiol, progesterone, adrenal androgens, and the AR antagonist, hydroxyflutamide, without an apparent effect on receptor levels, ligand binding kinetics, or DNA binding." | 3.71 | Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. ( Bentel, JM; Buchanan, G; Greenberg, NM; Han, G; Harris, JM; Horsfall, DJ; Marshall, VR; Matusik, RJ; Moore, N; Nahm, HS; Tilley, WD; Yang, M, 2001) |
| " This paper demonstrated that flutamide combined with leuprorelin acetate produced a significant reduction in the growth rate of Dunning R3327-H prostatic adenocarcinoma." | 3.70 | [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats]. ( Abe, F; Kuroiwa, S; Okada, M; Tomura, A, 1998) |
| "To assess the effectiveness of palladium 103 (Pd-103) brachytherapy in Stage T1 and T2 adenocarcinoma of the prostate." | 3.70 | Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. ( Behar, RJ; Cantor, A; Chovnick, SD; Huff, W; Otheguy, J; Perez, R; Sharkey, J; Solc, Z, 1998) |
| "To assess the effectiveness of palladium-103 brachytherapy in stage T1 and T2 adenocarcinoma of the prostate." | 3.70 | Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. ( Behar, RJ; Cantor, A; Chovnick, SD; Donohue, M; Huff, W; Otheguy, J; Perez, R; Rabinowitz, R; Sharkey, J; Solc, Z; Steele, J; Webster, C, 2000) |
| " A pilot study was undertaken to test the efficacy of flutamide (an antiandrogen) in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer." | 3.70 | Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. ( Greenberg, N; Kuliyev, E; Raghow, S; Steakley, M; Steiner, MS, 2000) |
| "Patients with bulky clinical Stage C adenocarcinoma of the prostate were given 3 months of hormone treatment consisting of oral Flutamide and monthly Zoladex injections prior to irradiation." | 3.69 | The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. ( Abellera, M; Chen, GT; Chiru, P; Hamilton, RJ; Ray, P; Spelbring, D; Vaida, F; Vijayakumar, S; Yang, FE, 1995) |
| "To investigate the effect of combination endocrine treatment (CET) or luteinising hormone releasing hormone agonist and flutamide on non-neoplastic prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma." | 3.69 | Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. ( Fabris, G; Magi-Galluzzi, C; Montironi, R; Muzzonigro, G; Polito, M; Prete, E, 1994) |
| "Three of 34 patients treated with a TAS regimen incorporating flutamide developed significant hepatic abnormalities: elevated transaminases [2] and fatal hepatic necrosis [1]." | 3.69 | Flutamide-induced liver toxicity including fatal hepatic necrosis. ( Chen, A; Crownover, RL; Fu, KK; Holland, J; Krieg, R; Roach, M; Young, BK, 1996) |
| "We report a primary squamous cell carcinoma of the prostate that developed in a 57-year-old man, 3 years after treatment with leuprolide and flutamide for Stage D1 adenocarcinoma of the prostate." | 3.69 | Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide. ( Braslis, KG; Civantos, F; Davi, RC; Nelson, E; Soloway, MS, 1995) |
| "The histopathology of 23 radical prostatectomies from patients with prostatic adenocarcinoma pretreated for 3-6 months with combination therapy including a luteinizing hormone-releasing hormone agonist and the antiandrogen drug flutamide was reviewed and compared with the pretreatment biopsies or transurethral resection material." | 3.68 | Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. ( Boivin, JC; Dupont, A; Labrie, F; Monfette, G; Pinault, S; Srigley, JR; Têtu, B, 1991) |
| "Twenty-one patients with advanced prostatic adenocarcinoma previously untreated with conventional endocrine therapy were treated with an oral non-steroidal antiandrogen, flutamide." | 3.66 | Experience with flutamide in previously untreated patients with advanced prostatic cancer. ( Sogani, PC; Whitmore, WF, 1979) |
| "The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial." | 2.77 | Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. ( Ahles, T; Gu, L; Halabi, S; Hussain, A; Kaplan, E; Kelly, WK; Monk, JP; Philips, G; Picus, J; Small, EJ; Vogelzang, N, 2012) |
| "Flutamide (750 g/d) was administered for 1 mo." | 2.77 | Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. ( Mazeron, JJ; Molinie, V; Mottet, N; Peneau, M; Richaud, P, 2012) |
| "To study whether use of neoadjuvant androgen deprivation therapy (N-ADT) combined with whole pelvic radiotherapy (WPRT) for high-risk prostate cancer patients was associated with survival benefit over prostate radiotherapy (PORT) only." | 2.74 | Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. ( Antczak, A; Baczyk, M; Kwias, Z; Martenka, P; Milecki, P; Skowronek, J, 2009) |
| "Men with localized but unfavorable-risk prostate cancer who were treated with RT and 6 months of planned combined AST appear to have an increased risk of recurrence when treated with less than as compared with 6 months of the antiandrogen." | 2.73 | Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. ( Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, B; Renshaw, AA, 2008) |
| "Among men with androgen independent prostate cancer, no clear association could be detected between body mass index and progression-free survival, overall survival or prostate specific antigen response." | 2.73 | Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. ( Crawford, ED; Goldman, B; Hussain, M; Klein, EA; Montgomery, RB; Page, S; Petrylak, DP; Tangen, CM, 2007) |
| "818 men with locally advanced prostate cancer were randomly assigned to: no androgen deprivation (ie, radiotherapy alone: 66 Gy in 33 fractions of 2 Gy per day over 6." | 2.71 | Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. ( Atkinson, C; Christie, D; D'Este, C; Denham, JW; Duchesne, G; Franklin, I; Joseph, D; Kovacev, O; Lamb, DS; Mameghan, H; Matthews, J; North, J; Poulsen, M; Spry, NA; Steigler, A; Tai, KH; Turner, S; Wynne, C, 2005) |
| "Pretreatment with flutamide increased the serum testosterone level, but the testosterone surge after leuprorelin administration was almost the same in all 5 treatment groups." | 2.70 | Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. ( Kumon, H; Maki, Y; Nasu, Y; Noda, M; Saika, T; Suyama, B; Tsushima, T; Yamato, T, 2001) |
| "The primary clinical events were disease progression and survival." | 2.69 | Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. ( Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ, 1999) |
| "To evaluate the efficacy of chemoendocrine therapy for the initial treatment of stage D2 prostate cancer, we conducted a prospective randomized study which compared combined androgen blockade alone to that combined with UFT." | 2.69 | [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT]. ( Akazawa, S; Aki, M; Hashine, K; Kuwahara, M; Sumiyoshi, Y; Takenaka, A; Yamamoto, A, 1999) |
| "Flutamide is a potent antiandrogen widely used in clinical practice for patients with metastatic prostate cancer." | 2.68 | Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. ( Hilsenbeck, SG; Razvillas, B; Rothenberg, ML; Sharma, A; Sharma, JJ; Stephens, CD, 1997) |
| "To compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer." | 2.68 | A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. ( Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N, 1995) |
| "A randomized, multicenter trial, double-blind for antiandrogen therapy, compared the antiandrogens bicalutamide and flutamide, each combined with luteinizing hormone-releasing hormone analogue therapy (LHRH-A) in 813 patients with Stage D2 prostate carcinoma." | 2.68 | A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. ( Block, NL; Chen, Y; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ, 1996) |
| "flutamide 3 times daily was evaluated prospectively before cessation of the flutamide." | 2.68 | Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. ( Dieringer, P; Herrada, J; Logothetis, CJ, 1996) |
| "Although the only opportunity to cure prostate cancer is treatment at an early stage, radical prostatectomy has remained relatively unpopular because 40-50% of prostate cancers estimated at diagnosis as confined to the prostate are found to be at a more advanced stage following histopathological analysis of the surgical specimen." | 2.67 | Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. ( Cusan, L; Diamond, P; Dupont, A; Fradet, Y; Gomez, J; Koutsilieris, M; Labrie, F; Lemay, M; Suburu, R; Têtu, B, 1993) |
| "All estramustine-treated patients lost their libido, whereas only 20 per cent of the patients treated with flutamide did so." | 2.66 | Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. ( Andersson, SO; Beckman, KW; Johansson, JE; Lingårdh, G; Zador, G, 1987) |
| "Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy." | 2.65 | Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. ( Sogani, PC; Vagaiwala, MR; Whitmore, WF, 1984) |
| " This technique has been used most commonly to treat prostate cancers in combination with hormonal therapy." | 2.42 | Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men. ( Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y, 2003) |
| "Unfortunately, every treatment for prostate cancer has adverse effects with negative impact in health-related quality of life." | 2.42 | Monotherapy in advanced prostate cancer: an overview. ( Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N, 2004) |
| "Ten cases of SIADH caused by prostatic cancer have been reported including the present case." | 2.41 | Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report. ( Abe, H; Ito, H; Miura, T; Nishimura, T; Oaki, Y; Oka, F; Uchikoba, T, 2000) |
| "Under the diagnosis of prostatic cancer with multiple pulmonary metastasis, we performed total androgen blockade (TAB) consisting of luteinizing hormone releasing hormone agonist and flutamide following dietylstilbestrol (DES) intravenous injection therapy." | 2.41 | [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report]. ( Fukuda, M; Fuse, H; Hirano, S; Takashima, H, 2002) |
| "We report a case of prostatic cancer in a 73-year-old man detected by abnormalities in chest X-ray and serum prostate specific antigen (PSA) level." | 2.41 | [Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report]. ( Hashimoto, H; Inada, F; Ishida, H; Kawakami, N; Kitahara, K; Masui, N; Saga, Y; Tokumitsu, M; Yachiku, S, 2001) |
| "Up-regulated PCDH1 promotes pancreatic cancer cell metastasis." | 1.91 | PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy. ( Chen, Y; Du, X; He, X; Ren, X; Tai, Y; Yi, X; Zou, X, 2023) |
| " The use of HIFU in combination with androgen deprivation was associated with a decrease in numerical density of microvessels in zones of tumor and non-tumor parenchyma in patients with relapses." | 1.48 | Status of the Microcirculatory Network as a Factor of Prognosis and Evaluation of Therapeutic Efficiency in Prostate Cancer Treated by High-Intensity Focused Ultrasound in Combination with Androgen Deprivation. ( Abdullaev, NA; Bakarev, MA; Kachesov, IV; Levin, VP; Neimark, AI, 2018) |
| "Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life." | 1.35 | Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. ( Dewilde, S; Kleinman, L; Lloyd, A; Penson, D, 2008) |
| "The present data suggest that those prostate cancer patients who have even marginally elevated adrenal androgens may especially benefit from combined androgen blockade." | 1.35 | Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. ( Belanger, A; Chertin, B; Farkas, A; Fridmans, A; Hartman, H; Labrie, F; Spitz, IM, 2009) |
| "More than 85% of men with prostate cancer die of other causes." | 1.34 | Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. ( Jennrich, R; Johnson, H; Lam, R; Scholz, M; Strum, S; Trilling, T, 2007) |
| "We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis." | 1.34 | [Mediastinal lymph nodes during the course of a metastatic prostate cancer]. ( Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S, 2007) |
| "The incidence and discovery rate of prostate cancer is increased in recent years; with advanced age and multiple organs dysfunction, the advanced prostate cancer patients have poor quality of life." | 1.33 | [Experience in treating advanced prostate cancer with bladder outlet obstruction]. ( Chen, JH; Kong, L; Sheng, XJ; Ye, M; Zhang, L; Zhu, YJ, 2005) |
| "We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer." | 1.33 | Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. ( Hiraoka, M; Kamoto, T; Kinoshita, H; Mitsumori, M; Mizowaki, T; Nagata, Y; Negoro, Y; Ogawa, O; Sasai, K; Sasaki, Y; Takayama, K, 2006) |
| "A 88-year-old man with prostate cancer was receiving non-steroidal anti-androgen therapy (flutamide, 375 mg/day)." | 1.32 | Interstitial pneumonitis related to flutamide monotherapy for prostate cancer. ( Fujimoto, N; Matsumoto, T; Nomura, M; Sato, H, 2004) |
| "During the diagnostic work-up, prostate cancer was diagnosed." | 1.32 | Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. ( Grigoriadis, N; Kallinikidis, T; Kalpidis, P; Karakolios, A; Kasapis, C, 2003) |
| "Once metastatic, prostate cancer was regarded as a systemic disease that is not amenable to surgical therapy." | 1.32 | Biochemical remission after resection of prostate cancer lung metastasis. ( Brooks, JD; Chao, DH; Higgins, JP, 2004) |
| "Four patients suffered bone fractures, none pathological." | 1.31 | A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. ( Baba, S; Egawa, S; Kuwao, S; Matsumoto, K; Mizoguchi, H; Takashima, R, 2000) |
| "Twenty selected patients with prostate cancer, who were treated with hormonal therapy and demonstrated biochemical downstaging by reduction of PSA prior to RP and bilateral pelvic node dissection at the Tohsei National Hospital between January 1997 and August 2001, are reported on." | 1.31 | Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse. ( Kiriyama, I; Nishimura, T; Ogaki, K; Ohba, S, 2002) |
| "In hemodialysis patients, few cases of prostate cancer have been reported until recently." | 1.31 | Prostate cancer with multiple lung metastases in a hemodialysis patient. ( Aoyagi, T; Hata, M; Hayakawa, K; Matsumoto, M; Miyaji, K, 2000) |
| "Eighteen patients with prostate cancer and 17 healthy subjects matched for age and body mass index were included." | 1.31 | Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. ( Bryc, W; Kokot, F; Nowicki, M, 2001) |
| "The flutamide therapy was immediately discontinued and this resulted in spontaneous remission (clinical and liver function test results returned to normal) during the next 8 weeks." | 1.31 | Flutamide-induced acute hepatitis in advanced prostate cancer patients. ( Kraus, I; Oguic, R; Vitezic, D, 2001) |
| "Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy." | 1.30 | Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. ( Colecchia, M; Colloi, D; Del Boca, C; Frigo, B; Guardamagna, A; Leopardi, O; Zucchi, A, 1997) |
| "Suramin has demonstrated modest activity against prostate cancer and is being investigated in clinical trials." | 1.30 | Acute renal failure in a patient receiving treatment with suramin. ( Harbour, D; Liebmann, J; Smith, A, 1997) |
| "Their density in prostatic cancer increases following hormonal therapy and varies in relation to the tumoral degree or histological evaluation, suggesting a role of neuroendocrine cells in human prostatic cancer." | 1.30 | Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. ( del Valle, M; Escaf, S; Guate, JL; Menendez, CL; Vega, JA, 1997) |
| "A seventy-three year-old patient with prostate cancer underwent radical prostatectomy, followed by total androgen brocking therapy using flutamide and LH-RH agonist." | 1.30 | [Fatal hepatic failure following hepatitis caused by flutamide: a case report]. ( Kinebuchi, Y; Murata, Y; Okaneya, T, 1999) |
| "A given prostate cancer patient's response to therapy may be predicted by following apoptotic and mitotic activity, as well as Ki-67 and p53 expression in repeated biopsies." | 1.30 | Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation. ( Bély, M; Lovász, S; Romics, I; Szegedi, Z; Szende, B; Torda, I, 1999) |
| "To compare disease progression and survival of patients with stage D1 adenocarcinoma after treatment with either early androgen ablation alone or combined with radical prostatectomy." | 1.30 | Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer. ( Lubos, W; Schmeller, N, 1997) |
| "Turosteride (FCE 26073) is a new, potent, and selective 5 alpha-reductase inhibitor." | 1.30 | Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. ( di Salle, E; Giudici, D; Zaccheo, T, 1997) |
| "Accordingly, the final diagnosis was prostate cancer (cT3N4M1, stage D2)." | 1.30 | [Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report]. ( Higashi, T; Maruyama, Y; Nagayoshi, J, 1999) |
| "Patients with node-positive prostate cancer that is regionally localized (T1-4, N1-3, M0) have a relatively poor prognosis when a single-treatment modality such as radical surgery, definitive radiotherapy, or androgen ablation is used." | 1.29 | Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. ( Pollack, A; Sands, ME; Zagars, GK, 1995) |
| "Secondary testicular tumors are very rare." | 1.29 | [Bilateral testicular metastasis of an adenocarcinoma of the prostate]. ( Agnanti, N; Bai, M; Giannakopoulos, X; Grammeniatis, E; Stefanou, D, 1994) |
| "We describe a florid xanthomatous histiocytic reaction in the pelvic lymph nodes of a patient treated with androgen deprivation therapy prior to radical prostatectomy." | 1.29 | Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy. ( Gormley, EA; Schned, AR, 1996) |
| "Flutamide is a nonsteroidal antiandrogen commonly used in the treatment of prostate cancer." | 1.29 | Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. ( Barbara, L; Cicognani, C; Malavolti, M; Morselli-Labate, AM; Sama, C, 1996) |
| "Metastases to the meninges from prostatic cancer are rare, accounting for less than 0." | 1.29 | Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. ( DeAngelis, LM; Mencel, PJ; Motzer, RJ, 1994) |
| "A 75-year-old patient presented with a superior vena cava syndrome (SVCS) lasting 3 years." | 1.29 | Metastatic carcinoma of the prostate presenting as a superior vena cava syndrome. ( Bellas, C; Hernanz, I; Molina, JP; Montalbán, C; Moreno, MA, 1993) |
| "in 1941, hormonal treatment of advanced prostatic cancer has been directed primarily at neutralizing testicular androgens by orchiectomy or estrogen therapy." | 1.27 | [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]. ( Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE, 1986) |
| "Patients (154) with clinical stage D2 prostate cancer with no previous endocrine therapy or chemotherapy received the combination therapy with the pure antiandrogen Flutamide and the LHRH agonist [D-Trp6]LHRH ethylamide for an average of 22 months (3-49 months)." | 1.27 | Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. ( Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lachance, R; Lacourciere, Y; Monfette, G, 1987) |
| "Three patients have died from prostate cancer while three have died from other causes, 93." | 1.27 | Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. ( Belanger, A; Bergeron, N; Borsanyi, JP; Cusan, L; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y, 1988) |
| "Ten men with prostatic cancer, stage T3M0 Nx or more, who were anxious to maintain sexual potency, were treated with flutamide." | 1.27 | Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency. ( Johansson, JE; Schnürer, LB; Stegmayr, B, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (9.74) | 18.7374 |
| 1990's | 87 (44.62) | 18.2507 |
| 2000's | 74 (37.95) | 29.6817 |
| 2010's | 13 (6.67) | 24.3611 |
| 2020's | 2 (1.03) | 2.80 |
| Authors | Studies |
|---|---|
| Du, X | 1 |
| Yi, X | 1 |
| Zou, X | 1 |
| Chen, Y | 2 |
| Tai, Y | 1 |
| Ren, X | 1 |
| He, X | 1 |
| Fukuoka, K | 1 |
| Teishima, J | 1 |
| Nagamatsu, H | 1 |
| Inoue, S | 1 |
| Hayashi, T | 1 |
| Mita, K | 1 |
| Shigeta, M | 1 |
| Kobayashi, K | 1 |
| Kajiwara, M | 1 |
| Kadonishi, Y | 1 |
| Tacho, T | 1 |
| Matsubara, A | 1 |
| Lawton, CAF | 2 |
| Lin, X | 1 |
| Hanks, GE | 1 |
| Lepor, H | 1 |
| Grignon, DJ | 2 |
| Brereton, HD | 1 |
| Bedi, M | 1 |
| Rosenthal, SA | 1 |
| Zeitzer, KL | 3 |
| Venkatesan, VM | 1 |
| Horwitz, EM | 2 |
| Pisansky, TM | 2 |
| Kim, H | 1 |
| Parliament, MB | 1 |
| Rabinovitch, R | 2 |
| Roach, M | 3 |
| Kwok, Y | 2 |
| Dignam, JJ | 1 |
| Sandler, HM | 2 |
| Bakarev, MA | 1 |
| Levin, VP | 1 |
| Kachesov, IV | 1 |
| Abdullaev, NA | 1 |
| Neimark, AI | 1 |
| Moughan, J | 1 |
| Dicker, AP | 1 |
| Gore, EM | 2 |
| Seider, MJ | 1 |
| Hsu, IC | 1 |
| Hartford, AC | 1 |
| Yamoah, K | 1 |
| Jones, CU | 2 |
| Michalski, JM | 1 |
| Lee, WR | 1 |
| Rotman, M | 2 |
| Pryzant, RM | 1 |
| Kim, HE | 1 |
| Thomas, CR | 1 |
| Shipley, WU | 3 |
| Zapatero, A | 1 |
| Guerrero, A | 1 |
| Maldonado, X | 1 |
| Alvarez, A | 1 |
| Gonzalez San Segundo, C | 1 |
| Cabeza Rodríguez, MA | 1 |
| Macias, V | 1 |
| Pedro Olive, A | 1 |
| Casas, F | 1 |
| Boladeras, A | 1 |
| de Vidales, CM | 1 |
| Vazquez de la Torre, ML | 1 |
| Villà, S | 1 |
| Perez de la Haza, A | 1 |
| Calvo, FA | 1 |
| Krauss, DJ | 1 |
| Hu, C | 1 |
| Bahary, JP | 1 |
| Souhami, L | 1 |
| Chafe, SM | 1 |
| Leibenhaut, MH | 1 |
| Narayan, S | 1 |
| Torres-Roca, J | 1 |
| Michalski, J | 1 |
| Donavanik, V | 1 |
| Sandler, H | 1 |
| McGowan, DG | 1 |
| D'Amico, AV | 4 |
| Chen, MH | 2 |
| Renshaw, AA | 4 |
| Loffredo, B | 1 |
| Kantoff, PW | 5 |
| Spitz, IM | 1 |
| Chertin, B | 1 |
| Fridmans, A | 1 |
| Farkas, A | 1 |
| Belanger, A | 9 |
| Hartman, H | 1 |
| Labrie, F | 17 |
| Alexander, A | 1 |
| Crook, J | 1 |
| Jones, S | 1 |
| Malone, S | 1 |
| Bowen, J | 1 |
| Truong, P | 1 |
| Pai, H | 1 |
| Ludgate, C | 1 |
| Milecki, P | 1 |
| Baczyk, M | 1 |
| Skowronek, J | 1 |
| Antczak, A | 1 |
| Kwias, Z | 1 |
| Martenka, P | 1 |
| Narimoto, K | 1 |
| Mizokami, A | 1 |
| Izumi, K | 1 |
| Mihara, S | 1 |
| Sawada, K | 1 |
| Sugata, T | 1 |
| Shimamura, M | 1 |
| Miyazaki, K | 1 |
| Nishino, A | 1 |
| Namiki, M | 1 |
| Armstrong, JG | 1 |
| Gillham, CM | 1 |
| Dunne, MT | 1 |
| Fitzpatrick, DA | 1 |
| Finn, MA | 1 |
| Cannon, ME | 1 |
| Taylor, JC | 1 |
| O'Shea, CM | 1 |
| Buckney, SJ | 1 |
| Thirion, PG | 1 |
| Pérez-Montaña, A | 1 |
| Navarro, JT | 1 |
| Juncà, J | 1 |
| Ribera, JM | 1 |
| Monk, JP | 1 |
| Halabi, S | 2 |
| Picus, J | 1 |
| Hussain, A | 1 |
| Philips, G | 1 |
| Kaplan, E | 1 |
| Ahles, T | 1 |
| Gu, L | 1 |
| Vogelzang, N | 2 |
| Kelly, WK | 1 |
| Small, EJ | 2 |
| Mottet, N | 1 |
| Peneau, M | 1 |
| Mazeron, JJ | 2 |
| Molinie, V | 1 |
| Richaud, P | 1 |
| Piccionello, AP | 1 |
| Pitarresi, G | 1 |
| Pace, A | 1 |
| Triolo, D | 1 |
| Picone, P | 1 |
| Buscemi, S | 1 |
| Giammona, G | 1 |
| Bolla, M | 1 |
| Fukuda, M | 1 |
| Takashima, H | 1 |
| Fuse, H | 1 |
| Hirano, S | 1 |
| Kiriyama, I | 1 |
| Ogaki, K | 1 |
| Ohba, S | 1 |
| Nishimura, T | 2 |
| Glass, TR | 1 |
| Tangen, CM | 4 |
| Crawford, ED | 8 |
| Thompson, I | 1 |
| Miller, NL | 1 |
| Bissonette, EA | 1 |
| Bahnson, R | 1 |
| Wilson, J | 1 |
| Theodorescu, D | 1 |
| Preston, DM | 1 |
| Torréns, JI | 1 |
| Harding, P | 1 |
| Howard, RS | 1 |
| Duncan, WE | 1 |
| McLeod, DG | 5 |
| Kaur, C | 1 |
| Thami, GP | 1 |
| Sciarra, A | 1 |
| Monti, S | 1 |
| Gentile, V | 1 |
| Mariotti, G | 1 |
| Cardi, A | 1 |
| Voria, G | 1 |
| Lucera, R | 1 |
| Di Silverio, F | 1 |
| Karasawa, K | 1 |
| Kaizu, T | 1 |
| Niibe, Y | 1 |
| Igaki, H | 1 |
| Shinohara, M | 1 |
| Tanaka, Y | 1 |
| Matsuda, T | 1 |
| Kosugi, M | 1 |
| Hanawa, Y | 1 |
| Momma, T | 1 |
| Saito, S | 1 |
| Hirose, S | 1 |
| Oh, WK | 1 |
| Manola, J | 2 |
| Bittmann, L | 1 |
| Brufsky, A | 2 |
| Kaplan, ID | 1 |
| Smith, MR | 1 |
| Kaufman, DS | 1 |
| Jani, AB | 1 |
| Basu, A | 1 |
| Abdalla, I | 1 |
| Connell, PP | 1 |
| Krauz, L | 1 |
| Vijayakumar, S | 2 |
| Sheski, FD | 1 |
| Henley, JD | 1 |
| Foster, RS | 1 |
| Einhorn, LH | 1 |
| Barqawi, AB | 1 |
| Moul, JW | 1 |
| Ziada, A | 1 |
| Handel, L | 1 |
| Karakolios, A | 1 |
| Kasapis, C | 1 |
| Kallinikidis, T | 1 |
| Kalpidis, P | 1 |
| Grigoriadis, N | 1 |
| Chao, DH | 1 |
| Higgins, JP | 1 |
| Brooks, JD | 1 |
| Faulkner, JR | 1 |
| Thompson, IM | 3 |
| Hirano, D | 1 |
| Eisenberger, M | 1 |
| Hussain, M | 2 |
| de Leval, J | 1 |
| Boca, P | 1 |
| Yousef, E | 1 |
| Nicolas, H | 1 |
| Jeukenne, M | 1 |
| Seidel, L | 1 |
| Bouffioux, C | 1 |
| Coppens, L | 1 |
| Bonnet, P | 1 |
| Andrianne, R | 1 |
| Wlatregny, D | 1 |
| Zwergel, T | 1 |
| Tahmatzopoulos, A | 1 |
| Wullich, B | 1 |
| Zwergel, U | 1 |
| Stöckle, M | 2 |
| Unteregger, G | 1 |
| Sato, N | 1 |
| Akakura, K | 1 |
| Isaka, S | 1 |
| Nakatsu, H | 1 |
| Tanaka, M | 1 |
| Ito, H | 2 |
| Masai, M | 1 |
| Loffredo, M | 3 |
| DellaCroce, A | 1 |
| Nomura, M | 1 |
| Sato, H | 1 |
| Fujimoto, N | 1 |
| Matsumoto, T | 1 |
| Baltogiannis, D | 1 |
| Giannakopoulos, X | 2 |
| Charalabopoulos, K | 1 |
| Sofikitis, N | 1 |
| Qian, LX | 1 |
| Hua, LX | 1 |
| Wu, HF | 1 |
| Sui, YG | 1 |
| Cheng, SG | 1 |
| Zhang, W | 1 |
| Li, J | 1 |
| Wang, XR | 1 |
| Negi, SS | 1 |
| Agarwal, A | 1 |
| Chaudhary, A | 1 |
| Sheng, XJ | 1 |
| Zhu, YJ | 1 |
| Ye, M | 1 |
| Chen, JH | 1 |
| Zhang, L | 1 |
| Kong, L | 1 |
| Denham, JW | 1 |
| Steigler, A | 1 |
| Lamb, DS | 1 |
| Joseph, D | 1 |
| Mameghan, H | 1 |
| Turner, S | 1 |
| Matthews, J | 1 |
| Franklin, I | 1 |
| Atkinson, C | 1 |
| North, J | 1 |
| Poulsen, M | 1 |
| Christie, D | 1 |
| Spry, NA | 1 |
| Tai, KH | 1 |
| Wynne, C | 1 |
| Duchesne, G | 1 |
| Kovacev, O | 1 |
| D'Este, C | 1 |
| Papaioannides, D | 1 |
| Korantzopoulos, P | 1 |
| Bouropoulos, C | 1 |
| Latsi, P | 1 |
| Fotinou, M | 1 |
| Orphanidou, D | 1 |
| Konski, A | 1 |
| Watkins-Bruner, D | 1 |
| Brereton, H | 1 |
| Feigenberg, S | 1 |
| Hanks, G | 2 |
| Yamamoto, S | 1 |
| Yonese, J | 1 |
| Kawakami, S | 1 |
| Tsukamoto, T | 1 |
| Ohkubo, Y | 1 |
| Tatokoro, M | 1 |
| Fukui, I | 1 |
| Mitsumori, M | 1 |
| Sasaki, Y | 1 |
| Mizowaki, T | 1 |
| Takayama, K | 1 |
| Nagata, Y | 1 |
| Hiraoka, M | 1 |
| Negoro, Y | 1 |
| Sasai, K | 1 |
| Kinoshita, H | 1 |
| Kamoto, T | 1 |
| Ogawa, O | 1 |
| Metzner, C | 1 |
| Nöldge, G | 1 |
| Delling, G | 1 |
| Oehler, U | 1 |
| Nawroth, P | 1 |
| Kasperk, C | 1 |
| Klokk, TI | 1 |
| Kurys, P | 1 |
| Elbi, C | 1 |
| Nagaich, AK | 1 |
| Hendarwanto, A | 1 |
| Slagsvold, T | 1 |
| Chang, CY | 1 |
| Hager, GL | 1 |
| Saatcioglu, F | 1 |
| Heymann, JJ | 1 |
| Benson, MC | 1 |
| O'Toole, KM | 1 |
| Malyszko, B | 1 |
| Brody, R | 1 |
| Vecchio, D | 1 |
| Schiff, PB | 1 |
| Mansukhani, MM | 1 |
| Ennis, RD | 1 |
| Mercader, M | 1 |
| Sengupta, S | 1 |
| Bodner, BK | 1 |
| Manecke, RG | 1 |
| Cosar, EF | 1 |
| Moser, MT | 1 |
| Ballman, KV | 1 |
| Wojcik, EM | 1 |
| Kwon, ED | 1 |
| Cho, YM | 1 |
| Takahashi, S | 1 |
| Asamoto, M | 1 |
| Suzuki, S | 1 |
| Tang, M | 1 |
| Shirai, T | 1 |
| Lloyd, A | 1 |
| Penson, D | 1 |
| Dewilde, S | 1 |
| Kleinman, L | 1 |
| Slovin, SF | 1 |
| Miquel, M | 1 |
| Soler, A | 1 |
| Vaqué, A | 1 |
| Ojanguren, I | 1 |
| Costa, J | 1 |
| Planas, R | 1 |
| Montgomery, RB | 1 |
| Goldman, B | 1 |
| Petrylak, DP | 1 |
| Page, S | 1 |
| Klein, EA | 1 |
| Lawton, CA | 3 |
| Bae, K | 1 |
| Pilepich, M | 1 |
| Shipley, W | 1 |
| Roca Edreira, A | 1 |
| Aguilera Tubet, C | 1 |
| Villanueva Peña, A | 1 |
| Ballestero Diego, R | 1 |
| Zubillaga Guerrero, S | 1 |
| Scholz, M | 1 |
| Lam, R | 1 |
| Strum, S | 1 |
| Jennrich, R | 1 |
| Johnson, H | 1 |
| Trilling, T | 1 |
| Vollmer, R | 1 |
| McMahon, E | 1 |
| Sanford, B | 1 |
| Archer, L | 1 |
| Vogelzang, NJ | 3 |
| Sartor, AO | 1 |
| Hussain, MH | 1 |
| Eisenberger, MA | 3 |
| Parab, M | 1 |
| Fontana, JA | 1 |
| Chapman, RA | 1 |
| Mills, GM | 1 |
| Raghavan, D | 1 |
| Tutton, PJ | 1 |
| Barkla, DH | 1 |
| Sogani, PC | 3 |
| Vagaiwala, MR | 1 |
| Whitmore, WF | 3 |
| Soloway, MS | 5 |
| Ahmed, T | 1 |
| Benedetto, P | 1 |
| Yagoda, A | 1 |
| Watson, RC | 1 |
| Scher, HI | 1 |
| Herr, HW | 1 |
| Pertschuk, L | 1 |
| Isaacs, JT | 1 |
| Weissman, RM | 1 |
| Coffey, DS | 1 |
| Scott, WW | 1 |
| Yang, FE | 1 |
| Chen, GT | 1 |
| Ray, P | 1 |
| Vaida, F | 1 |
| Chiru, P | 1 |
| Hamilton, RJ | 1 |
| Spelbring, D | 1 |
| Abellera, M | 1 |
| Keizur, JJ | 1 |
| Kane, CJ | 1 |
| North, R | 1 |
| Leidich, RB | 1 |
| Rozanski, TA | 1 |
| Faerber, GJ | 1 |
| Johnson, TL | 1 |
| Cusan, L | 10 |
| Gomez, JL | 4 |
| Dupont, A | 15 |
| Diamond, P | 4 |
| Lemay, M | 4 |
| Moore, S | 1 |
| Andros, EA | 1 |
| Danesghari, F | 1 |
| Schulman, CC | 1 |
| Sassine, AM | 1 |
| Armas, OA | 1 |
| Aprikian, AG | 1 |
| Melamed, J | 1 |
| Cordon-Cardo, C | 1 |
| Cohen, DW | 1 |
| Erlandson, R | 1 |
| Fair, WR | 3 |
| Reuter, VE | 1 |
| Montironi, R | 3 |
| Magi-Galluzzi, C | 1 |
| Muzzonigro, G | 3 |
| Prete, E | 1 |
| Polito, M | 3 |
| Fabris, G | 1 |
| Van de Voorde, WM | 1 |
| Elgamal, AA | 1 |
| Van Poppel, HP | 1 |
| Verbeken, EK | 1 |
| Baert, LV | 1 |
| Lauweryns, JM | 1 |
| Sands, ME | 1 |
| Pollack, A | 1 |
| Zagars, GK | 1 |
| Cheson, BD | 1 |
| Kaplan, RS | 1 |
| Phillips, PH | 1 |
| Brenner, PC | 1 |
| Rettig, WJ | 1 |
| Sanz-Moncasi, MP | 1 |
| Reuter, V | 1 |
| Aprikian, A | 1 |
| Old, LJ | 1 |
| Garin-Chesa, P | 1 |
| Schellhammer, P | 1 |
| Sharifi, R | 3 |
| Block, N | 1 |
| Soloway, M | 1 |
| Venner, P | 1 |
| Patterson, AL | 3 |
| Sarosdy, M | 1 |
| Jones, J | 1 |
| Kolvenbag, G | 1 |
| Cher, ML | 1 |
| Shinohara, K | 1 |
| Breslin, S | 1 |
| Vapnek, J | 1 |
| Carroll, PR | 2 |
| Whittington, R | 1 |
| Malkowicz, B | 1 |
| Barnes, MM | 1 |
| Broderick, GA | 1 |
| Van Arsdalen, K | 1 |
| Dougherty, MJ | 1 |
| Wein, AJ | 1 |
| Dran, G | 1 |
| Luthy, IA | 2 |
| Molinolo, AA | 2 |
| Montecchia, F | 1 |
| Charreau, EH | 1 |
| Pasqualini, CD | 1 |
| Lanari, C | 2 |
| Koutsilieris, M | 2 |
| Pilepich, MV | 3 |
| Krall, JM | 1 |
| al-Sarraf, M | 1 |
| John, MJ | 2 |
| Doggett, RL | 1 |
| Sause, WT | 1 |
| Abrams, RA | 2 |
| Rubin, P | 2 |
| Bai, M | 1 |
| Grammeniatis, E | 1 |
| Stefanou, D | 1 |
| Agnanti, N | 1 |
| Braslis, KG | 1 |
| Davi, RC | 1 |
| Nelson, E | 1 |
| Civantos, F | 2 |
| Magi Galluzzi, C | 1 |
| Giannulis, I | 1 |
| Diamanti, L | 1 |
| Scarpelli, M | 1 |
| Morote, J | 1 |
| Lorente, JA | 1 |
| Vallejo, C | 1 |
| Narayan, P | 1 |
| Lowe, BA | 2 |
| Gomez, J | 3 |
| Suburu, R | 3 |
| Fradet, Y | 3 |
| Têtu, B | 5 |
| Ferguson, J | 1 |
| Zincke, H | 1 |
| Ellison, E | 1 |
| Bergstrahl, E | 1 |
| Bostwick, DG | 1 |
| Mencel, PJ | 1 |
| DeAngelis, LM | 1 |
| Motzer, RJ | 1 |
| Carrascosa, M | 1 |
| Perez-Castrillon, JL | 1 |
| Mendez, MA | 1 |
| Cillero, L | 1 |
| Valle, R | 1 |
| Benson, RC | 1 |
| Blumenstein, BA | 2 |
| Spicer, D | 1 |
| Spaulding, JT | 1 |
| Berrevoets, CA | 1 |
| Veldscholte, J | 1 |
| Mulder, E | 1 |
| Rosman, AS | 1 |
| Frissora-Rodeo, C | 1 |
| Marshall, AT | 1 |
| Reiter, BP | 1 |
| Paronetto, F | 1 |
| Montalbán, C | 1 |
| Moreno, MA | 1 |
| Molina, JP | 1 |
| Hernanz, I | 1 |
| Bellas, C | 1 |
| Voges, GE | 1 |
| Mottrie, AM | 1 |
| Fichtner, J | 1 |
| Mappes, C | 1 |
| Störkel, S | 1 |
| Hohenfellner, R | 1 |
| Schned, AR | 1 |
| Gormley, EA | 1 |
| Herrada, J | 1 |
| Dieringer, P | 1 |
| Logothetis, CJ | 1 |
| Crownover, RL | 1 |
| Holland, J | 1 |
| Chen, A | 1 |
| Krieg, R | 1 |
| Young, BK | 1 |
| Fu, KK | 2 |
| Van der Kwast, TH | 2 |
| Regueiro López, JC | 1 |
| Ruiz Alvarez Cienfuegos, F | 1 |
| Leva Vallejo, M | 1 |
| Requena Tapia, MJ | 1 |
| Merchan García, JA | 1 |
| Prieto Castro, R | 1 |
| Alvarez Kindelan, J | 1 |
| Pinto, JE | 1 |
| Andréjak, M | 1 |
| Nguyen-Khac, E | 1 |
| Decocq, G | 1 |
| Capron, JP | 1 |
| Schellhammer, PF | 2 |
| Block, NL | 2 |
| Venner, PM | 2 |
| Sarosdy, MF | 2 |
| Kolvenbag, GJ | 2 |
| Cicognani, C | 1 |
| Malavolti, M | 1 |
| Morselli-Labate, AM | 1 |
| Sama, C | 1 |
| Barbara, L | 1 |
| Minardi, D | 1 |
| Caplan, R | 1 |
| Sarkar, FH | 1 |
| Hammond, EH | 1 |
| Forman, JD | 1 |
| Mesic, J | 1 |
| Pajak, TF | 1 |
| Cox, JD | 1 |
| Albertsen, PC | 1 |
| Aaronson, NK | 1 |
| Muller, MJ | 1 |
| Keller, SD | 1 |
| Ware, JE | 1 |
| Zaccheo, T | 1 |
| Giudici, D | 1 |
| di Salle, E | 1 |
| Schmeller, N | 1 |
| Lubos, W | 1 |
| López López, C | 1 |
| Quilez Fenoll, JM | 1 |
| Gómez Ruiz, JJ | 1 |
| López López, AF | 1 |
| Romero Maroto, YJ | 1 |
| Patel, H | 1 |
| Rhee, E | 1 |
| Zimmern, PE | 1 |
| Fernández Peña, CM | 1 |
| Morano Amado, LE | 1 |
| Montes Santiago, J | 1 |
| Fachal, C | 1 |
| Candas, B | 1 |
| Kagebayashi, Y | 1 |
| Ozono, S | 2 |
| Takashima, K | 1 |
| Yoshikawa, M | 2 |
| Hayashi, Y | 1 |
| Kaneko, Y | 1 |
| Maruyama, Y | 3 |
| Hirao, Y | 2 |
| Okajima, E | 2 |
| Figg, WD | 1 |
| Kroog, G | 1 |
| Duray, P | 1 |
| Walther, MM | 1 |
| Patronas, N | 1 |
| Sartor, O | 1 |
| Reed, E | 1 |
| Pantel, K | 1 |
| Enzmann, T | 1 |
| Köllermann, J | 1 |
| Caprano, J | 1 |
| Riethmüller, G | 1 |
| Köllermann, MW | 1 |
| Krijnen, JL | 1 |
| Bogdanowicz, JF | 1 |
| Seldenrijk, CA | 1 |
| Mulder, PG | 1 |
| Fontaine-Rothe, P | 1 |
| Berlane, K | 1 |
| Rieker, P | 1 |
| Jiroutek, M | 1 |
| Kaplan, I | 1 |
| Kaufman, D | 1 |
| Kantoff, P | 1 |
| Colecchia, M | 1 |
| Frigo, B | 1 |
| Del Boca, C | 1 |
| Guardamagna, A | 1 |
| Zucchi, A | 1 |
| Colloi, D | 1 |
| Leopardi, O | 1 |
| Markiewicz, L | 1 |
| Gurpide, E | 1 |
| Cellini, N | 1 |
| Luzi, S | 1 |
| Morganti, AG | 1 |
| Balducci, M | 1 |
| Caiazza, A | 1 |
| Salvi, G | 1 |
| Trodella, L | 1 |
| Valentini, V | 1 |
| Smith, A | 1 |
| Harbour, D | 1 |
| Liebmann, J | 1 |
| Losa, M | 1 |
| Grasso, M | 1 |
| Giugni, E | 1 |
| Mortini, P | 1 |
| Acerno, S | 1 |
| Giovanelli, M | 1 |
| Gómez Veiga, F | 1 |
| Lorenzo Patiño, MJ | 1 |
| Díaz Bermúdez, J | 1 |
| Duarte Novo, J | 1 |
| Alvarez Castelo, L | 1 |
| Chantada Abal, V | 1 |
| Sánchez Rodríguez, J | 1 |
| González Martín, M | 1 |
| Guate, JL | 1 |
| Escaf, S | 1 |
| Menendez, CL | 1 |
| del Valle, M | 1 |
| Vega, JA | 1 |
| Unger, PD | 1 |
| Wang, Q | 1 |
| Gordon, RE | 1 |
| Stock, R | 1 |
| Stone, N | 1 |
| Tran, TA | 1 |
| Jennings, TA | 1 |
| Ross, JS | 1 |
| Nazeer, T | 1 |
| Tomura, A | 1 |
| Kuroiwa, S | 1 |
| Okada, M | 1 |
| Abe, F | 1 |
| Sharma, JJ | 1 |
| Razvillas, B | 1 |
| Stephens, CD | 1 |
| Hilsenbeck, SG | 1 |
| Sharma, A | 1 |
| Rothenberg, ML | 1 |
| Reid, MB | 1 |
| Glode, LM | 1 |
| Sharkey, J | 2 |
| Chovnick, SD | 2 |
| Behar, RJ | 2 |
| Perez, R | 2 |
| Otheguy, J | 2 |
| Solc, Z | 2 |
| Huff, W | 2 |
| Cantor, A | 2 |
| Miller, G | 1 |
| Loehrer, PJ | 1 |
| Wilding, G | 2 |
| Sears, K | 1 |
| Culkin, DJ | 1 |
| Bueschen, AJ | 1 |
| Montecchia, MF | 1 |
| Lamb, C | 1 |
| Pazos, P | 1 |
| Charreau, E | 1 |
| Vanzulli, S | 1 |
| Matsushima, H | 1 |
| Goto, T | 1 |
| Hosaka, Y | 1 |
| Kitamura, T | 1 |
| Kawabe, K | 1 |
| Okaneya, T | 1 |
| Murata, Y | 1 |
| Kinebuchi, Y | 1 |
| Kelley, RP | 1 |
| Sumiyoshi, Y | 1 |
| Hashine, K | 1 |
| Kuwahara, M | 1 |
| Aki, M | 1 |
| Yamamoto, A | 1 |
| Akazawa, S | 1 |
| Takenaka, A | 1 |
| Nagayoshi, J | 1 |
| Higashi, T | 1 |
| Ortiz Rey, JA | 1 |
| Da Silva, EA | 1 |
| Antón Badiola, I | 1 |
| Alvarez Alvarez, C | 1 |
| Zungri Telo, E | 1 |
| de la Fuente Buceta, A | 1 |
| Szende, B | 1 |
| Romics, I | 1 |
| Torda, I | 1 |
| Bély, M | 1 |
| Szegedi, Z | 1 |
| Lovász, S | 1 |
| Schrader, TJ | 1 |
| Cooke, GM | 1 |
| Kurita, M | 1 |
| Kato, Y | 1 |
| Tamura, Y | 1 |
| Suzuki, K | 1 |
| Yamanaka, H | 1 |
| Egawa, S | 1 |
| Takashima, R | 1 |
| Matsumoto, K | 1 |
| Mizoguchi, H | 1 |
| Kuwao, S | 1 |
| Baba, S | 1 |
| Rabinowitz, R | 1 |
| Steele, J | 1 |
| Webster, C | 1 |
| Donohue, M | 1 |
| Raghow, S | 1 |
| Kuliyev, E | 1 |
| Steakley, M | 1 |
| Greenberg, N | 1 |
| Steiner, MS | 1 |
| Granter, SR | 1 |
| del Vecchio, MT | 1 |
| Tripodi, SA | 1 |
| Arcuri, F | 1 |
| Pergola, L | 1 |
| Hako, L | 1 |
| Vatti, R | 1 |
| Cintorino, M | 1 |
| Abe, H | 1 |
| Oka, F | 1 |
| Miura, T | 1 |
| Uchikoba, T | 1 |
| Oaki, Y | 1 |
| Rodríguez Gómez, SJ | 1 |
| Martínez Moreno, J | 1 |
| Martín Arribas, MI | 1 |
| Pérez Villoria, A | 1 |
| De la Serna Higuera, C | 1 |
| Betancourt González, A | 1 |
| Betancourt, JE | 1 |
| Cecchi, M | 1 |
| Sepich, CA | 1 |
| Bertolini, L | 1 |
| Catastini, M | 1 |
| Di Benedetto, A | 1 |
| Ippolito, C | 1 |
| Pazzagli, I | 1 |
| Summonti, D | 1 |
| Bonadio, AG | 1 |
| Fiorentini, L | 1 |
| Yamaguchi, A | 1 |
| Iwai, A | 1 |
| Moriya, A | 1 |
| Yoshida, K | 1 |
| Samma, S | 1 |
| Wilson, KS | 1 |
| Ludgate, CM | 1 |
| Wilson, AG | 1 |
| Alexander, AS | 1 |
| Buchanan, G | 1 |
| Yang, M | 1 |
| Harris, JM | 1 |
| Nahm, HS | 1 |
| Han, G | 1 |
| Moore, N | 1 |
| Bentel, JM | 1 |
| Matusik, RJ | 1 |
| Horsfall, DJ | 1 |
| Marshall, VR | 1 |
| Greenberg, NM | 1 |
| Tilley, WD | 1 |
| Lovely, LP | 1 |
| Appa Rao, KB | 1 |
| Gui, Y | 1 |
| Lessey, BA | 1 |
| Hayakawa, K | 1 |
| Matsumoto, M | 1 |
| Aoyagi, T | 1 |
| Miyaji, K | 1 |
| Hata, M | 1 |
| Nowicki, M | 1 |
| Bryc, W | 1 |
| Kokot, F | 1 |
| Tokumitsu, M | 1 |
| Inada, F | 1 |
| Kitahara, K | 1 |
| Kawakami, N | 1 |
| Masui, N | 1 |
| Ishida, H | 2 |
| Saga, Y | 1 |
| Hashimoto, H | 1 |
| Yachiku, S | 1 |
| Leibowitz, RL | 1 |
| Tucker, SJ | 1 |
| Tsushima, T | 1 |
| Nasu, Y | 1 |
| Saika, T | 1 |
| Maki, Y | 1 |
| Noda, M | 1 |
| Suyama, B | 1 |
| Yamato, T | 1 |
| Kumon, H | 1 |
| Gandy, S | 1 |
| Almeida, OP | 1 |
| Fonte, J | 1 |
| Lim, D | 1 |
| Waterrus, A | 1 |
| Spry, N | 1 |
| Flicker, L | 1 |
| Martins, RN | 1 |
| Rapoport, J | 1 |
| Noël, G | 1 |
| Winter, K | 1 |
| Mesic, JB | 1 |
| Sause, W | 1 |
| Lawton, C | 1 |
| Machtay, M | 1 |
| Grignon, D | 1 |
| Kraus, I | 1 |
| Vitezic, D | 1 |
| Oguic, R | 1 |
| Sprangers, MA | 1 |
| Moinpour, CM | 1 |
| Moynihan, TJ | 1 |
| Patrick, DL | 1 |
| Revicki, DA | 1 |
| Jorion, JL | 1 |
| Tremblay, M | 1 |
| Kaskas, M | 1 |
| Sauvage, L | 1 |
| Hattab, B | 1 |
| Zaragoza, MR | 1 |
| Grossman, HB | 1 |
| Pinault, S | 2 |
| Gagnon, J | 1 |
| Monfette, G | 7 |
| Dawson, NA | 1 |
| Weiss, RB | 1 |
| Linehan, WM | 1 |
| Frank, JA | 1 |
| Jacob, JL | 1 |
| Gelmann, EP | 1 |
| Srigley, JR | 1 |
| Boivin, JC | 1 |
| Emond, J | 5 |
| Manhès, G | 1 |
| Bergeron, N | 2 |
| Lacourcière, Y | 5 |
| Pineault, S | 1 |
| Prout, GR | 2 |
| Keating, MA | 1 |
| Griffin, PP | 1 |
| Schiff, SF | 1 |
| Monfette, JE | 1 |
| Giguere, M | 3 |
| Borsanyi, JP | 3 |
| Lachance, R | 3 |
| Brochu, M | 1 |
| Kung, TT | 1 |
| Mingo, GG | 1 |
| Siegel, MI | 1 |
| Watnick, AS | 1 |
| Johansson, JE | 3 |
| Andersson, SO | 2 |
| Beckman, KW | 2 |
| Zador, G | 2 |
| Stegmayr, B | 1 |
| Schnürer, LB | 1 |
| St-Arnaud, R | 1 |
| Kelly, SJ | 1 |
| Lingårdh, G | 1 |
| Irwin, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE III TRIAL COMPARING WHOLE PELVIC IRRADIATION FOLLOWED BY A CONEDOWN BOOST TO BOOST IRRADIATION ONLY AND COMPARING NEOADJUVANT TO ADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS)[NCT00769548] | Phase 3 | 1,322 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer.[NCT02175212] | Phase 3 | 362 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Randomised Comparison of Short and Protracted Neoadjuvant Hormonal Therapy Prior to Radiation Therapy of High Risk Localized Prostate Cancer[NCT00003734] | Phase 3 | 276 participants (Anticipated) | Interventional | 1998-12-31 | Active, not recruiting | ||
| Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial[NCT00243646] | Phase 3 | 6 participants (Actual) | Interventional | 2004-08-31 | Terminated (stopped due to poor accrual) | ||
| Postoperative Hypofractionated Radiation Therapy and Hormonal Therapy in Patients With Prostate Cancer: A Phase II Trial[NCT04249154] | Phase 2 | 77 participants (Anticipated) | Interventional | 2019-09-03 | Recruiting | ||
| Phase II Randomized Clinical Trial Comparing 3-D Conformal Radiation Therapy (RT) vs. Intensity Modulated Radiation Therapy in Post- Prostatectomy Prostate Cancer Patients[NCT02678520] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn (stopped due to PI no longer at institution. Study terminated prior to enrolling subjects.) | ||
| A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer[NCT00116220] | Phase 3 | 206 participants (Actual) | Interventional | 1995-09-30 | Completed | ||
| A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma[NCT01040624] | 77 participants (Actual) | Interventional | 2009-12-31 | Completed | |||
| Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy[NCT00969111] | 70 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | |||
| A Phase II Study of Dose-Escalated Proton-Based Radiation Therapy Delivered With a Simultaneous Integrated Boost (SIB) to Intraprostatic Tumors (IPT) Visible on Pretreatment Magnetic Resonance Image[NCT03624660] | 100 participants (Anticipated) | Interventional | 2018-09-24 | Recruiting | |||
| A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE[NCT00767286] | Phase 3 | 0 participants | Interventional | Completed | |||
| Phase II Trial of Maximal Androgen Deprivation Followed by Conformal External Beam Radiotherapy With Continued Androgen Deprivation for Clinically Localized Prostate Cancer[NCT00003124] | Phase 2 | 105 participants (Anticipated) | Interventional | 1997-05-31 | Completed | ||
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| ULTRA-HYPO Fractionated (UHF) Compared to Moderate-HYPO Fractionated (MHF) Prostate IGRT With HDR Brachytherapy BOOST : A Phase 1-2 Study.[NCT05786742] | 205 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | |||
| Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer[NCT00932672] | Phase 2 | 45 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to slow recruitment, lack of funding and PI transferred) | ||
| Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial. (PCS-XI)[NCT05820633] | 500 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | |||
| Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy[NCT03296124] | 0 participants (Actual) | Observational | 2017-12-07 | Withdrawn (stopped due to This project currently does not have any subjects enrolled due to other PI priorities.) | |||
| PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY[NCT00002889] | Phase 2 | 180 participants (Actual) | Interventional | 1997-05-31 | Completed | ||
| A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer[NCT01875250] | Phase 2 | 38 participants (Actual) | Interventional | 2013-07-22 | Completed | ||
| Collection of Blood From Patients With Prostate Cancer[NCT00923221] | 1,000 participants (Anticipated) | Observational | 2007-02-28 | Recruiting | |||
| Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)[NCT02303327] | Phase 3 | 296 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml). (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Long Term Androgen Deprivation | 90 |
| Short Term Androgen Deprivation | 81 |
Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse (NCT02175212)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Long Term Androgen Deprivation | 177 |
| Short Term Androgen Deprivation | 173 |
Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI). (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Long Term Androgen Deprivation | 94 |
| Short Term Androgen Deprivation | 83 |
Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause. (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Long Term Androgen Deprivation | 95 |
| Short Term Androgen Deprivation | 86 |
"Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.~Scoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer-Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.~CV events were defined according to the World Health Organization criteria" (NCT02175212)
Timeframe: 5 years
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Grade 2 of more rectal toxicity | Grade 2 of more urinary toxicity | Cardiovascular | |
| Long Term Androgen Deprivation | 11.1 | 8.2 | 17.6 |
| Short Term Androgen Deprivation | 7.6 | 7.3 | 7.2 |
Number of participants that experienced acute grade 3 or higher, treatment-related toxicity based on CTCAE version 3.0 criteria. (NCT01040624)
Timeframe: 6 months after the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| HR-A | 1 |
| HR-B | 3 |
Normal testosterone is 270-1070 nd/dL. (NCT01875250)
Timeframe: 84 days
| Intervention | ng/dl (Median) |
|---|---|
| All Participants | 834 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01875250)
Timeframe: Date treatment consent signed to date off study, approximately 43 months and 13 days for Arm A, and 78 months and 6 days for Arm B.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 19 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 19 |
Median PSA change would be considered optimal. (NCT01875250)
Timeframe: 84 days
| Intervention | Percent change (Median) |
|---|---|
| Arm A - Enzalutamide for 3 Months | -99 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | -99 |
Growth rate was measured using the growth rate equation -f(t) = exp (-d*t) + exp (g*t) -1 where exp is the base of the natural algorithm, e = 2.7182 and t is days since treatment started. The tumor growth rate equation measures Prostate Specific Antigen (PSA) rise over time. The UOM is unitless because this is a way to measure PSA kinetics. (NCT01875250)
Timeframe: 7 months
| Intervention | unitless (Number) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 0.031 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 0.030 |
VEGF was measured by the enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantitation of assay was 9.0 pg/ml. (NCT01875250)
Timeframe: 30 Days After the Start of Course 1 and Course 2 of Enzalutamide
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 192 | 165.04 |
PSA recovery is defined as the return above baseline PSA in participants with normal testosterone and non-metastatic, castration sensitive prostate cancer. (NCT01875250)
Timeframe: up to 41 months
| Intervention | Days (Median) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 224 | 189 |
11 reviews available for flutamide and Adenocarcinoma
| Article | Year |
|---|---|
[Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Dru | 2002 |
Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Ch | 2003 |
Monotherapy in advanced prostate cancer: an overview.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality T | 2004 |
[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Flutamide; Hepatic | 1996 |
[Fulminant liver failure with a fatal outcome due to flutamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Fatal Outcome; Flutamide; Hep | 1997 |
Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Inap | 2000 |
[Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug | 2001 |
[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; C | 2001 |
Assessing meaningful change in quality of life over time: a users' guide for clinicians.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Competence; Clinical | 2002 |
[Endometrioid adenocarcinoma of the prostate. Apropos of a case, review of the literature].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Humans; Leuprolide; | 1992 |
Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
Topics: Adenocarcinoma; Anilides; Canada; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Hu | 1989 |
59 trials available for flutamide and Adenocarcinoma
| Article | Year |
|---|---|
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Dis | 2017 |
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Canada; Chemoradiotherapy; Dose Frac | 2018 |
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Horm | 2015 |
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Biopsy; Combined Modality Therapy; Di | 2015 |
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 2008 |
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
Topics: Adenocarcinoma; Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; D | 2010 |
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; H | 2009 |
A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; | 2011 |
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineo | 2012 |
Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemoradiotherapy; Dise | 2012 |
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormona | 2003 |
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2003 |
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antin | 2003 |
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hor | 2003 |
Ten-year survival in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Disease-Free Survival; Double-Blind Method; Flutamide; F | 2003 |
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; D | 2002 |
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progres | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2004 |
Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Double-Blind Method; Female; | 2006 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Disease-Free Survival; Flutamide; Gos | 2005 |
Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Flutam | 2007 |
Early effects of pharmacological androgen deprivation in human prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Leuprolide; Male; Neoplasms, Hormone- | 2007 |
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Disease-F | 2007 |
Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Follow-Up Studies; | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Caus | 2008 |
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Mi | 2008 |
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Fre | 2008 |
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Anilides; Bone Neoplasms; Clinical Trials as Topic; F | 1984 |
Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 1993 |
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Division; Combined Modality Therapy; Diploidy; Flutamide; Goserelin; Humans; Ma | 1994 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Comb | 1995 |
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Disease-Free Survival; Flutamide; Follow-Up Studies | 1995 |
Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Flutamide; Goserelin; Humans; Ma | 1995 |
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 1993 |
Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Carcinoma in Situ; Case-Control Studies; Combined Modali | 1994 |
The use of flutamide in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Huma | 1993 |
Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; M | 1996 |
[Prognosis significance of prostatic markers in patients with prostatic adenocarcinoma undergoing total hormonal blockade].
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Fluta | 1995 |
Histopathological effects of androgen deprivation in prostatic cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Fl | 1996 |
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Double-Blind Method | 1996 |
[Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Flutamide; Gonadotropin-Relea | 1996 |
Neoadjuvant hormonal therapy: the Canadian experience.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Canada; Chemotherapy, Adjuvant; Drug Therapy, Combinatio | 1997 |
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Fl | 1997 |
[Neoadjuvant combined hormonal therapy and radiotherapy with external beam irradiation in prostatic carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Follow- | 1997 |
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Female; Flutamide; | 1997 |
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Combined Modal | 1998 |
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agent | 1999 |
[Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Anti | 1999 |
A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; | 2000 |
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Horm | 2001 |
Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flut | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, | 2001 |
[The role of LH-RH analogues in the treatment of prostate cancer. Report of a conference organized by ICI-Pharma laboratories (part 2)].
Topics: Adenocarcinoma; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Neoplasm Staging; Orc | 1991 |
A pilot trial of chemohormonal therapy for metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug E | 1992 |
Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Canada; Flutamide; H | 1990 |
Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.
Topics: Adenocarcinoma; Anilides; Canada; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Hu | 1989 |
Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Anilides; Bone Neoplasms; Estramustine; Flutamide; Follow-Up Studies; Humans; | 1988 |
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Topics: Adenocarcinoma; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy | 1988 |
Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Bone Neoplasms; Estramustine; Flutamide; Humans; | 1987 |
126 other studies available for flutamide and Adenocarcinoma
| Article | Year |
|---|---|
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Topics: Adenocarcinoma; Biomarkers; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Ne | 2023 |
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chlormadinone Acetate; Flut | 2020 |
Status of the Microcirculatory Network as a Factor of Prognosis and Evaluation of Therapeutic Efficiency in Prostate Cancer Treated by High-Intensity Focused Ultrasound in Combination with Androgen Deprivation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antigens, CD34; Antineoplastic Agents | 2018 |
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Buserelin; Diarrhea; Flutamide; Gas | 2009 |
Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
Topics: Adenocarcinoma; Adrenal Glands; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Cell Line, | 2010 |
[Spontaneous complete remission in two patients with chronic lymphocytic leukemia].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Female; Flutamide; Human | 2011 |
Fluorinated and pegylated polyaspartamide derivatives to increase solubility and efficacy of Flutamide.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Chromatograph | 2012 |
The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approach.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Flutamide; Humans; Leuprolide; Male; Prostatic Neop | 2012 |
Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Flu | 2002 |
Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Brachytherapy; C | 2003 |
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Amino Acids; Androgen Antagonists; Androgens; Anilides | 2002 |
Flutamide-induced photosensitivity: is it a forme fruste of lupus?
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Lupu | 2003 |
[Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Carcinoma, Neuroendocrine; Cell Differentiati | 2003 |
Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; | 2003 |
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2003 |
Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Bilirubin; Biomarkers, | 2003 |
Biochemical remission after resection of prostate cancer lung metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; | 2004 |
Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures.
Topics: Adenocarcinoma; Androgen Antagonists; Apoptosis; Cell Division; Cell Survival; Cysteine Proteinase I | 2004 |
Interstitial pneumonitis related to flutamide monotherapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Flutamide; Humans; Lung Di | 2004 |
Anemia in patients on combined androgen block therapy for prostate cancer.
Topics: Adenocarcinoma; Adult; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Combined Modal | 2004 |
[Experience in treating advanced prostate cancer with bladder outlet obstruction].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antigens, Neoplasm; Flutamide; Humans | 2005 |
Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Flutamide; Humans; Male; Prostatic Neoplasms; | 2005 |
Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Co | 2006 |
Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Biomarkers, Tumor; Cohort Studies; Drug Therapy, Combina | 2006 |
[Bone metastasis of prostatic cancer imitating Paget's sarcoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neopla | 2006 |
Ligand-specific dynamics of the androgen receptor at its response element in living cells.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Chromatin Asse | 2007 |
Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Animals, Genetically Modified; Antigens, Viral, Tumor | 2007 |
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Choice Behavi | 2008 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormon | 2007 |
Suspected cross-hepatotoxicity of flutamide and cyproterone acetate.
Topics: Acute Disease; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Androgen Antagonists; Antineoplastic A | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bon | 2007 |
Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Moda | 2007 |
The influence of androgens, anti-androgens, and castration on cell proliferation in the jejunal and colonic crypt epithelia, and in dimethylhydrazine-induced adenocarcinoma of rat colon.
Topics: Adenocarcinoma; Anilides; Animals; Castration; Cell Division; Colon; Colonic Neoplasms; Dimethylhydr | 1982 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonad | 1984 |
Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide.
Topics: Adenocarcinoma; Adult; Aged; Anilides; Binding Sites; Dihydrotestosterone; Drug Evaluation; Estradio | 1984 |
Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
Topics: Acid Phosphatase; Adenocarcinoma; Animals; Castration; Diethylstilbestrol; Disease Models, Animal; F | 1980 |
The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Goserelin; Human | 1995 |
Adenocarcinoma of the prostate metastatic to the choroid of the eye.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Choroid Neoplasms; Flutamide; Humans; Leuprol | 1995 |
Massive locally extensive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Constipation; Flutamide; Humans; Leuprolide; Male; | 1994 |
Diagnosis of low back pain, secondary to prostate metastasis to the lumbar spine, by digital rectal examination and serum prostate-specific antigen.
Topics: Adenocarcinoma; Aged; Back Pain; Flutamide; Humans; Lumbar Vertebrae; Male; Orchiectomy; Postoperati | 1994 |
Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bo | 1994 |
Neoadjuvant hormonal deprivation before radical prostatectomy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biopsy; | 1993 |
Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma in Situ; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasin | 1994 |
Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Chromogranin A; Chromogranins; Estra | 1994 |
Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation.
Topics: Adenocarcinoma; Adult; Aged; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hormone; Humans; | 1995 |
Clinical trials referral resource. Prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Comb | 1994 |
TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antigens, Neoplasm; Bone Neoplasms; Flutamide; Glycoproteins | 1995 |
Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Flutamid | 1995 |
Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Blood Physiological Phenomena; Cell Division; Dexamet | 1995 |
Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy.
Topics: Adenocarcinoma; Combined Modality Therapy; Flutamide; Humans; Male; Neoplasm Staging; Prostate-Speci | 1993 |
[Bilateral testicular metastasis of an adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Combined Modality Therapy; Flutamide; Humans; Male; Orchiectom | 1994 |
Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Flutamide; Humans; Leupro | 1995 |
Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Ho | 1993 |
[Fluamide withdrawal syndrome].
Topics: Adenocarcinoma; Aged; Flutamide; Humans; Male; Prostatic Neoplasms; Substance Withdrawal Syndrome | 1994 |
Neoadjuvant hormonal therapy and radical prostatectomy for clinical stage C carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Diethylstilbestrol; Flutamide; Humans; Leuprolide; Mal | 1994 |
Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 1994 |
Malignant pleural effusion from prostatic adenocarcinoma resolved with hormonal therapy.
Topics: Adenocarcinoma; Aged; Flutamide; Humans; Leuprolide; Male; Pleural Effusion, Malignant; Pleural Neop | 1994 |
Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Topics: Adenocarcinoma; Alanine; Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Blotting, Wes | 1993 |
Cholestatic hepatitis following flutamide.
Topics: Adenocarcinoma; Aged; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Flutamide; | 1993 |
Metastatic carcinoma of the prostate presenting as a superior vena cava syndrome.
Topics: Adenocarcinoma; Aged; Biopsy; Flutamide; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Prostatic | 1993 |
Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Thera | 1995 |
Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Flutamide-induced liver toxicity including fatal hepatic necrosis.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Live | 1996 |
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Topics: Adenocarcinoma; Androgen Antagonists; Drug Therapy, Combination; Epithelial Cells; Epithelium; Fluta | 1996 |
[Fulminant hepatitis caused by flutamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Chemical and Drug Induced Liver Injury; Fatal | 1996 |
Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 1996 |
Effects of neoadjuvant androgen deprivation therapy on prostatic cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Case-Control Studies; Chemotherapy, Adjuvant; Flutamide; | 1996 |
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Cl | 1997 |
Health-related quality of life among patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Combined Chemothera | 1997 |
Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstenedione; Animals; Antineoplastic Agents, Hormo | 1997 |
Early endocrine therapy versus radical prostatectomy combined with early endocrine therapy for stage D1 prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progressio | 1997 |
[Total androgen blockade for prostate cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Flutamide; Gonadotropin-Releasing Hor | 1997 |
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic Agents, Hormona | 1997 |
Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemo | 1997 |
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cell Differentiation; Dise | 1997 |
Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Flutamide; Humans; | 1997 |
Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays.
Topics: Adenocarcinoma; Alkaline Phosphatase; Androgen Antagonists; Androgens; Breast Neoplasms; Cyproterone | 1997 |
Acute renal failure in a patient receiving treatment with suramin.
Topics: Acute Kidney Injury; Adenocarcinoma; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic | 1997 |
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Diagno | 1997 |
[Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; | 1997 |
Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; | 1997 |
Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Amyloidosis; Androgen Antagonists; Antineoplastic Agents, Hormonal; beta 2-Mic | 1997 |
Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Female; Flutamide; Huma | 1998 |
[Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 1998 |
Flutamide induced lupus.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Lupus Erythematosus, Systemic; Male; | 1998 |
Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Androgen Antagonists; Antineoplastic Agent | 1998 |
Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
Topics: Adenocarcinoma; Androgens; Animals; Binding Sites; Estradiol; Female; Flutamide; Glucocorticoids; Go | 1999 |
Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Antigens, Neoplasm; Antineoplastic Agents, Ho | 1999 |
[Fatal hepatic failure following hepatitis caused by flutamide: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Fatal Outcome; | 1999 |
[Serum concentrations of flutamide and goserelin in a prostate cancer patient with obstructive nephropathy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Goserelin; H | 1999 |
["Evanescent" prostate carcinoma].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy, Needle; Combine | 1999 |
Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Apoptosis; Flutamide; H | 1999 |
Examination of selected food additives and organochlorine food contaminants for androgenic activity in vitro.
Topics: Adenocarcinoma; Androgens; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Cell Survival; Chlord | 2000 |
[A case of prostate cancer treated with combined androgen-blockade].
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Diethylstilbestrol; Flutamide; Humans; | 2000 |
A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic | 2000 |
Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biop | 2000 |
Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Anticarcinogenic Agents; Blotting, Western; Crosses, | 2000 |
Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemother | 2000 |
Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplast | 2000 |
[Fulminant liver failure induced by flutamide].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Flutamide; Humans; Liver Failure; Male; Prostatic Neopla | 2000 |
Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Biopsy; Clinical Trials, Phase II as T | 2000 |
[Adenoid cystic carcinoma of the prostate. Clinical case].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Carcinoma, Adenoid Cysti | 2000 |
Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chi-Square Distribution; Flut | 2000 |
Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Binding Sites; Cell Line; COS Cells; Dihyd | 2001 |
Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa).
Topics: Adenocarcinoma; Alkaline Phosphatase; Androgens; Cell Differentiation; Cell Nucleus; Diethylstilbest | 2000 |
Prostate cancer with multiple lung metastases in a hemodialysis patient.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Therapy, Combinati | 2000 |
Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Appetite | 2001 |
Chemical andropause and amyloid-beta peptide.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Androgen Antagoni | 2001 |
Oncogenic osteomalacia.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Cholecalciferol; Disease Progression; Fatal Outcome; Flutamide | 2000 |
Flutamide-induced acute hepatitis in advanced prostate cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; C | 2001 |
Experience with flutamide in previously untreated patients with advanced prostatic cancer.
Topics: Adenocarcinoma; Aged; Anilides; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms | 1979 |
Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Drug Resistance; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; L | 1992 |
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Androgen | 1992 |
Objective treatment response to endocrine therapy in metastatic prostate cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Combined Modality Therapy; Estrogens; Flutamide; Humans; Lymphatic M | 1992 |
Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasin | 1992 |
Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.
Topics: Adenocarcinoma; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Immuno | 1991 |
Long-term experience with flutamide in patients with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Diethylstilbestrol; Flutamide; Humans; Male; Midd | 1989 |
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Flutam | 1986 |
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Topics: Adenocarcinoma; Androgens; Anilides; Combined Modality Therapy; Evaluation Studies as Topic; Flutami | 1987 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstene | 1988 |
Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma.
Topics: Adenocarcinoma; Adrenalectomy; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Che | 1988 |
Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic C | 1988 |
Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency.
Topics: Adenocarcinoma; Aged; Anilides; Fertility; Flutamide; Humans; Male; Middle Aged; Prostate; Prostatic | 1988 |
Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
Topics: Adenocarcinoma; Anilides; Animals; Biological Assay; Drug Therapy, Combination; Flutamide; Gonadotro | 1986 |
A new antiprostatic agent for treatment of prostatic carcinoma.
Topics: Adenocarcinoma; Anilides; Flutamide; Gynecomastia; Humans; Male; Neoplasm Metastasis; Prostatic Neop | 1973 |